Weight gain, obesity, and psychotropic prescribing (Q34557537)

3 August 2017

1 reference

title

Weight gain, obesity, and psychotropic prescribing (English)

1 reference

3 August 2017

0 references

1 reference

Nikhil Nihalani

1

1 reference

3 August 2017

Thomas L Schwartz

series ordinal

2

1 reference

3 August 2017

Umar A Siddiqui

series ordinal

3

1 reference

3 August 2017

James L Megna

series ordinal

4

1 reference

3 August 2017

17 January 2011

1 reference

3 August 2017

1 reference

3 August 2017

2011

1 reference

3 August 2017

893629

1 reference

Creative Commons Attribution 3.0 Unported

3 August 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Pharmacological management of appetite expression in obesity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Pharmacologic therapies for obesity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Aripiprazole in schizophrenia and schizoaffective disorder: A review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Immersion treatment of childhood and adolescent obesity: the first review of a promising intervention

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Drugs in the pipeline for the obesity market

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Asenapine versus olanzapine in acute mania: a double-blind extension study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Common dietary supplements for weight loss.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Dietary supplements for body-weight reduction: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Consensus development conference on antipsychotic drugs and obesity and diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

A review of the effect of atypical antipsychotics on weight

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Use of topiramate in treatment-resistant bipolar spectrum disorders.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Body weight changes associated with psychopharmacology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Topiramate treatment of bipolar spectrum disorders: a retrospective chart review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

A study of quetiapine: efficacy and tolerability in psychotic adolescents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Mirtazapine versus fluoxetine in the treatment of panic disorder

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Antipsychotic-induced weight gain: a review of the literature

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight gain associated with psychotropic drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Bodyweight gain with atypical antipsychotics. A comparative review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

How to help your patients lose weight: current therapy for obesity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight gain and antidepressants

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Atypical antipsychotics and weight gain--a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Antipsychotic-induced weight gain: a comprehensive research synthesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Effects of clozapine on the delta- and kappa-opioid receptors and the G-protein-activated K+ (GIRK) channel expressed in Xenopus oocytes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight gain in epileptic patients during treatment with valproic acid: a retrospective study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Valvular heart disease associated with fenfluramine-phentermine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Function and regulation of the beta 3-adrenoceptor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Bodyweight change as an adverse effect of drug treatment. Mechanisms and management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Use and abuse of appetite-suppressant drugs in the treatment of obesity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Lithium and body weight gain.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Placebo controlled double-blind trial of fluvoxamine maleate in the obese

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Monoamine oxidase inhibitors and weight gain.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Imipramine and weight gain during the treatment of recurrent depression.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight gain, increased appetite, and excessive food intake induced by carbamazepine.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Sibutramine in weight control: a dose-ranging, efficacy study.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Nortriptyline and weight change in depressed patients over 60

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight gain among schizophrenic patients treated with clozapine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series

7 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Weight loss associated with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Long‐term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Weight changes during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Genetic variants of the serotonin system and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Clozapine in adolescent inpatients with acute mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Use of portion-controlled entrees enhances weight loss in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Cognitive behavior therapy for weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Effectiveness of chromium in atypical depression: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

Metformin for weight loss in pediatric patients taking psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Psychotropic drug-induced weight gain alleviated with orlistat: a case series

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Topiramate for reversing atypical antipsychotic weight gain

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

The apparent effects of ziprasidone on plasma lipids and glucose.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Changes in weight during a 1-year trial of fluoxetine

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Phasic craving for carbohydrate observed with citalopram.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Comparison of bupropion and trazodone for the treatment of major depression.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Bupropion and amitriptyline in the treatment of depressed patients.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3034985

Adding cognitive therapy to dietetic treatment is associated with less relapse in obesity

27 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F893629

A double-blind randomized placebo-controlled trial of sibutramine

21 January 2018

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

12 December 2020

Sibutramine--a review of clinical efficacy

1 reference

12 December 2020

Mirtazapine compared with paroxetine in major depression

1 reference

12 December 2020

Sibutramine: a review of the pharmacology of a novel anti-obesity agent

1 reference

12 December 2020

Mode of action of orlistat

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group

1 reference

12 December 2020

How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/893629

1 reference

3 August 2017

1 reference

3 August 2017

1 reference